No Picture
News

Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the pricing […]

No Picture
Los Angeles Biotech Trending News

Alpha Cognition to Present at LD Micro Main Event

VANCOUVER, British Columbia–(BUSINESS WIRE)—- $ACOG–Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, […]

No Picture
News

Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic

SAN DIEGO: SAN DIEGO, Oct. 8, 2021 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a collaboration with renowned contemporary artist, Jorge Rodriguez-Gerada best known for his urban large-scale mural portraits, to create an […]

No Picture
Los Angeles Biotech Trending News

Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis

WILMINGTON, Del.–(BUSINESS WIRE)–Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is being developed by AstraZeneca in collaboration […]

News

Flagship turns to Novartis HR guru in latest addition; David Grainger saddles up to new position at Centessa while Pfizer’s Rod MacKenzie prepares to ride into the sunset

David Grainger ? In a development that just seemed to add up neatly given Medicxi’s involvement with Centessa, the brainchild of Francesco de Rubertis has named fellow Medicxi co-founder David Grainger as chief innovation officer. […]